drugset
drugset / Trial / NCT03505060

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

NCT03505060 ↗

Phase 1 Withdrawn National Institute of Allergy and Infectious Diseases (NIAID)
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of the IHV01 protein vaccine primed and co-administered with HIV DNA CON-S env vaccine in healthy, HIV-1-uninfected adults.

Timeline

Start
2019-01-01
Primary completion
2019-05
Completion
2019-11-11

Outcome

Outcome not reported

Stopped: “One of the study products is no longer available for clinical trial use.”

Drugs

EvaluationDrugModalityDoseRoute
Subject DNA CON-S env Vaccine 4 mg Intramuscular
Subject IHV01 Vaccine 150 ug Intramuscular

Indications

HIV infectious disease